Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 7
2004 6
2005 16
2006 15
2007 18
2008 20
2009 19
2010 23
2011 26
2012 20
2013 19
2014 18
2015 17
2016 10
2017 8
2018 11
2019 15
2020 10
2021 7
2022 1
2023 4
2024 7
2025 3
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

256 results

Results by year

Filters applied: . Clear all
Page 1
Testing for GW501516 (cardarine) in human hair using LC/MS-MS and confirmation by LC/HRMS.
Kintz P, Ameline A, Gheddar L, Raul JS. Kintz P, et al. Drug Test Anal. 2020 Jul;12(7):980-986. doi: 10.1002/dta.2802. Epub 2020 Apr 25. Drug Test Anal. 2020. PMID: 32298044
GW501516, also known as GW-1516 or cardarine and endurobol, is a peroxisome proliferator-activated receptor delta (PPAR-delta) agonist. ...Both athletes and amateurs can abuse GW501516 as the drug can be easily obtained via the Internet. Since January 2009, t …
GW501516, also known as GW-1516 or cardarine and endurobol, is a peroxisome proliferator-activated receptor delta (PPAR-delta) …
Five Novel Polymorphs of Cardarine/GW501516 and Their Characterization by X-ray Diffraction, Computational Methods, Thermal Analysis and a Pharmaceutical Perspective.
Turza A, Pascuta P, Muresan-Pop M, Mare L, Borodi G, Popescu V. Turza A, et al. Pharmaceutics. 2024 May 7;16(5):623. doi: 10.3390/pharmaceutics16050623. Pharmaceutics. 2024. PMID: 38794285 Free PMC article.
GW501516, also known by the name of cardarine, is a synthetic peroxisome-proliferator-activated receptor delta (PPR-delta) agonist agent developed for applications in the treatment of metabolic disorders and cardiovascular diseases. ...
GW501516, also known by the name of cardarine, is a synthetic peroxisome-proliferator-activated receptor delta (PPR-delta) ago …
GW501516 facilitated tumor immune escape by inhibiting phagocytosis.
Qian J, Guo Y, Khan B, Shi J, Hou Y. Qian J, et al. Eur J Pharmacol. 2025 May 15;995:177418. doi: 10.1016/j.ejphar.2025.177418. Epub 2025 Feb 22. Eur J Pharmacol. 2025. PMID: 39993702
In this study, qPCR analysis revealed that GW501516 treatment upregulated CD47 gene expression in colon cancer cells. Additionally, GW501516 increased membrane-associated CD47 protein levels in these cells. ...Crucially, PPARdelta knockout abolished GW501516- …
In this study, qPCR analysis revealed that GW501516 treatment upregulated CD47 gene expression in colon cancer cells. Additionally, …
Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages☆.
Lefere S, Puengel T, Hundertmark J, Penners C, Frank AK, Guillot A, de Muynck K, Heymann F, Adarbes V, Defrêne E, Estivalet C, Geerts A, Devisscher L, Wettstein G, Tacke F. Lefere S, et al. J Hepatol. 2020 Oct;73(4):757-770. doi: 10.1016/j.jhep.2020.04.025. Epub 2020 Apr 29. J Hepatol. 2020. PMID: 32360434
METHODS: Lanifibranor or selective PPARalpha (fenofibrate), PPARgamma (pioglitazone) and PPARdelta (GW501516) agonists were therapeutically administered in choline-deficient, amino acid-defined high-fat diet (CDAA-HFD)- and Western diet (WD)-fed mouse models of NAFLD. ...
METHODS: Lanifibranor or selective PPARalpha (fenofibrate), PPARgamma (pioglitazone) and PPARdelta (GW501516) agonists were therapeut …
Novel Solid Forms of Cardarine/GW501516 and Their Characterization by X-Ray Diffraction, Thermal, Computational, FTIR, and UV Analysis.
Turza A, Bosca M, Muresan-Pop M, Mare L, Borodi G, Popescu V. Turza A, et al. Pharmaceutics. 2025 Jan 23;17(2):152. doi: 10.3390/pharmaceutics17020152. Pharmaceutics. 2025. PMID: 40006519 Free PMC article.
A total of four new solid forms were obtained: a new polymorph of cardarine (C(21)H(18)F(3)NO(3)S(2)), the cardarine: 4,4'-bipyridine cocrystal (C(21)H(18)F(3)NO(3)S(2).0.5C(10)H(8)N(2)), the cardarine methanol solvate (C(21)H(18)F(3)NO(3)S(2).CH(3)OH), and t …
A total of four new solid forms were obtained: a new polymorph of cardarine (C(21)H(18)F(3)NO(3)S(2)), the cardarine: 4,4'-bip …
GW-501516 GlaxoSmithKline/Ligand.
Pelton P. Pelton P. Curr Opin Investig Drugs. 2006 Apr;7(4):360-70. Curr Opin Investig Drugs. 2006. PMID: 16625823 Review.
GlaxoSmithKline and Ligand are developing GW-501516, a peroxisome proliferator-activator receptor-delta agonist for the potential treatment of dyslipidemia. ...
GlaxoSmithKline and Ligand are developing GW-501516, a peroxisome proliferator-activator receptor-delta agonist for the potent …
[Effects of GW501516 on the proliferation of pulmonary artery smooth muscle cells induced by hypoxia and its mechanisms].
Chen CG, He LQ, Tian LQ, Yi CF. Chen CG, et al. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2022 Mar;38(2):119-125. doi: 10.12047/j.cjap.6211.2022.020. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2022. PMID: 36031568 Chinese.
PASMCs were incubated with 100 nmol/L GW501516 and ( or ) protein kinase B (AKT) agonist SC79 for 24 h to explore related mechanisms of GW501516 in regulating the proliferation. ...Compared with the 100 nmol/L GW501516 hypoxia group, AKT agonist SC79 reversed …
PASMCs were incubated with 100 nmol/L GW501516 and ( or ) protein kinase B (AKT) agonist SC79 for 24 h to explore related mechanisms …
PPARbeta/delta agonist GW501516 inhibits TNFalpha-induced repression of adiponectin and insulin receptor in 3T3-L1 adipocytes.
Kim WJ, Lee W, Jung Y, Jang HJ, Kim YK, Kim SN. Kim WJ, et al. Biochem Biophys Res Commun. 2019 Mar 19;510(4):621-628. doi: 10.1016/j.bbrc.2019.02.013. Epub 2019 Feb 8. Biochem Biophys Res Commun. 2019. PMID: 30739791
TNFalpha treatment reduced adiponectin expression at the end of differentiation. This effect was reversed by GW501516 co-treatment with TNFalpha. TNFalpha treatment decreased adipogenic marker genes such as PPARgamma, aP2, resistin, and GLUT4, and GW501516 reversed …
TNFalpha treatment reduced adiponectin expression at the end of differentiation. This effect was reversed by GW501516 co-treatment wi …
Inhibitory Effect of PPARdelta Agonist GW501516 on Proliferation of Hypoxia-induced Pulmonary Arterial Smooth Muscle Cells by Regulating the mTOR Pathway.
Chen CG, Yi CF, Chen CF, Tian LQ, Li LW, Yang L, Li ZM, He LQ. Chen CG, et al. Curr Med Sci. 2023 Oct;43(5):979-987. doi: 10.1007/s11596-023-2757-y. Epub 2023 Aug 22. Curr Med Sci. 2023. PMID: 37606736
Then PASMCs were treated with 100 nmol/ L GW501516, 100 nmol/L mammalian target of rapamycin (mTOR) inhibitor rapamycin and/or 2 mol/L mTOR activator MHY1485 to explore the molecular mechanisms by which GW501516 reduces the proliferation of PASMCs. ...Moreover, MHY …
Then PASMCs were treated with 100 nmol/ L GW501516, 100 nmol/L mammalian target of rapamycin (mTOR) inhibitor rapamycin and/or 2 mol …
GW501516-Mediated Targeting of Tetraspanin 15 Regulates ADAM10-Dependent N-Cadherin Cleavage in Invasive Bladder Cancer Cells.
Barbaud A, Lascombe I, Péchery A, Arslan S, Kleinclauss F, Fauconnet S. Barbaud A, et al. Cells. 2024 Apr 19;13(8):708. doi: 10.3390/cells13080708. Cells. 2024. PMID: 38667323 Free PMC article.
For antitumor molecules to inhibit N-cadherin function, they should be complete and not cleaved. We first showed that the GW501516, an agonist of the nuclear receptor PPARbeta/delta, decreased Tspan15 and prevented N-cadherin cleavage thus decreasing NTF. ...By targeting T …
For antitumor molecules to inhibit N-cadherin function, they should be complete and not cleaved. We first showed that the GW501516, a …
256 results